Macro Strategist, Saxo Capital Markets

Kay Van-Petersen

Macro Strategist

Saxo Capital Markets

Thematic (Sector/Industry)

<ul><li>Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; </li><li>In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. </li></ul>

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. 

Index Rebalance and Special Situations Coverage, Quiddity Advisors

Anjana Amarasuriya

Index Rebalance and Special Situations Coverage

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The SP 500 index tracks the 500 largest US-listed names and is one of the most highly-tracked indices in the world.</li>
<li>The rankings used for the March 2026 index rebal event will be based on yesterday's (4th March 2026) opening prices. The announcement will be made after the close on Friday.</li>
<li>In this insight, we take a look at our final expectations for ADDs/DELs (along with a tracker of all live spinoff/M&amp;A events which affect the index the next few quarters).</li>
</ul>


The SP 500 index tracks the 500 largest US-listed names and is one of the most highly-tracked indices in the world.
The rankings used for the March 2026 index rebal event will be based on yesterday's (4th March 2026) opening prices. The announcement will be made after the close on Friday.
In this insight, we take a look at our final expectations for ADDs/DELs (along with a tracker of all live spinoff/M&amp;A events which affect the index the next few quarters).


Quiddity Leaderboard SP500/600 Mar26 Rebal: Final Expectations

<ul>
<li>The SP 500 index tracks the 500 largest US-listed names and is one of the most highly-tracked indices in the world. </li>
<li>We expect two changes during the March 2026 regular rebalance. One intra-review index change is possible but unlikely before the regular rebalance is announced.</li>
<li>One name stands out as more interesting than the others.</li>
</ul>


The SP 500 index tracks the 500 largest US-listed names and is one of the most highly-tracked indices in the world. 
We expect two changes during the March 2026 regular rebalance. One intra-review index change is possible but unlikely before the regular rebalance is announced.
One name stands out as more interesting than the others.


Quiddity Leaderboard SP500/600 Mar26 Rebal: Base Date Is Less Than A Month Away

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Hologic, Inc., a prominent player in healthcare solutions for women's health, reported its financial results for the third quarter of fiscal 2025.</li><li>The results were a mixed bag with both positive advancements and some challenges that the company aimed to address.</li><li>Hologic's total revenue for the third quarter was $1.024 billion, representing a modest year-over-year growth of 0.4%, which exceeded the guidance by approximately $14 million.</li></ul>

Hologic, Inc., a prominent player in healthcare solutions for women's health, reported its financial results for the third quarter of fiscal 2025.The results were a mixed bag with both positive advancements and some challenges that the company aimed to address.Hologic's total revenue for the third quarter was $1.024 billion, representing a modest year-over-year growth of 0.4%, which exceeded the guidance by approximately $14 million.

Hologic's Latest Product Pipeline & Sales Shakeup—Is This the Start of a Multi-Year Rally?

<ul><li>Hologic Inc. reported its financial performance for the second quarter of fiscal 2025, showcasing a nuanced blend of strategic achievements and challenges impacting future growth.</li><li>The company reported total revenue of $1.005 billion, a slight decrease of 0.5% in constant currency terms, yet aligning with the higher end of guidance expectations.</li><li>Non-GAAP earnings per share remained consistent with the previous year at $1.03, buoyed by improvements in gross margin and aided by share buybacks and a lower tax rate.</li></ul>

Hologic Inc. reported its financial performance for the second quarter of fiscal 2025, showcasing a nuanced blend of strategic achievements and challenges impacting future growth.The company reported total revenue of $1.005 billion, a slight decrease of 0.5% in constant currency terms, yet aligning with the higher end of guidance expectations.Non-GAAP earnings per share remained consistent with the previous year at $1.03, buoyed by improvements in gross margin and aided by share buybacks and a lower tax rate.

How Hologic Stabilized Its Breast Health Business & Is Positioned for Explosive Growth!

United States

Hologic, Inc. is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hologic Inc (HOLX US)

Never Trust A Swiss Central Banker

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central...

Kay Van-Petersen

Quiddity Leaderboard SP500/600 Mar26 Rebal: Final Expectations

Final expectations are presented for the S&P500 March 2026 rebalance, with SP 600 DELETEs also presented, which we think represent good trade ideas...

Anjana Amarasuriya

Quiddity Leaderboard SP500/600 Mar26 Rebal: Base Date Is Less Than A Month Away

The base date is approaching next week and this is a good time to revisit the insight. Lamb Weston has replaced Molina Healthcare in our top...

Anjana Amarasuriya

Hologic's Latest Product Pipeline & Sales Shakeup—Is This the Start of a Multi-Year Rally?

Hologic, Inc., a prominent player in healthcare solutions for women's health, reported its financial results for the third quarter of fiscal...

Baptista Research

How Hologic Stabilized Its Breast Health Business & Is Positioned for Explosive Growth!

Hologic Inc. reported its financial performance for the second quarter of fiscal 2025, showcasing a nuanced blend of strategic achievements and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)